Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.
A smart money expert says Summit Therapeutics is looking better now and worth paying more for. When experts change their minds to become more positive, it's worth noticing what they see that they didn't see before.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.